Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17.9M Buy
68,308
+17,544
+35% +$4.5M 0.7% 22
2026
Q2
$12.8M Sell
50,764
-430
-0.8% -$92.5K 0.52% 31
2026
Q1
$11.1M Buy
51,194
+828
+2% +$184K 0.5% 30
2025
Q4
$11.5M Buy
50,366
+13,096
+35% +$2.98M 0.51% 35
2025
Q3
$8.63M Buy
37,270
+799
+2% +$163K 0.62% 25
2025
Q2
$6.77M Buy
36,471
+745
+2% +$138K 0.53% 34
2025
Q1
$7.48M Sell
35,726
-294
-0.8% -$57.2K 0.66% 21
2024
Q4
$6.4M Buy
36,020
+168
+0.5% +$30.9K 0.53% 35
2024
Q3
$7.08M Buy
+35,852
New +$6.69M 0.62% 24

Other funds holding ABBV

BFC Planning's ABBV Position: Q3 2026 in Review

BFC Planning increased its AbbVie (ABBV) stake by 35% in Q3 2026, buying an estimated $4.5M and bringing the position to 68,308 shares worth $17.9M. The position accounts for 0.7% of the portfolio, ranked #22.

BFC Planning first reported a position in ABBV in Q3 2024 and has held it in 9 quarters since. 3,830 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • BFC Planning held 68,308 shares of AbbVie worth $17.9M as of Q3 2026.
  • BFC Planning bought 17,544 AbbVie shares in Q3 2026, an estimated $4.5M.
  • AbbVie made up 0.7% of BFC Planning's portfolio in Q3 2026, its #22 holding.
  • BFC Planning first reported a position in AbbVie in Q3 2024 and has held it in 9 quarters since.
  • 3,830 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.